Trial Profile
A Phase 1, Randomised Double-blind, Placebo-controlled STUDY of Single and Repeated Ascending doses in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6001
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tanimilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Chiesi Farmaceutici
- 18 May 2016 Status changed from recruiting to completed, as per an abstract presented at the 112th International Conference of the American Thoracic Society.
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 16 Mar 2015 New trial record